Skip to content

Bone Marrow Versus Adipose Autologous Mesenchymal Stem Cells for the Treatment of Knee Osteoarthritis

Bone Marrow Versus Adipose Autologous Mesenchymal Stem Cells for the Treatment of Knee Osteoarthritis: A Randomized Non Blind Controlled Clinical Trial

Status
UNKNOWN
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04351932
Enrollment
54
Registered
2020-04-17
Start date
2020-06-07
Completion date
2021-09-07
Last updated
2020-04-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Osteo Arthritis Knee

Keywords

Mesenchymal stem cell

Brief summary

Mesenchymal stem cells (MSC) are stromal cells that have the ability to self-renew and also exhibit multilineage differentiation. MSCs can be isolated from a variety of tissues, such as umbilical cord, bone marrow, and adipose tissue. The multipotent properties of MSCs make them a promising option for the treatment of osteoarthritis (OA). Bone marrow mesenchymal stem cells (BM-MSC) and adipose derived mesenchymal stem cells (AD-MSC) have been used separately to treat OA. The aim of the present study will be to compare in a randomized non blind controlled clinical trial 3 types of intra-articular injections containing MSC populations obtained from two clinically relevant sources: BM-MSC, AD-MSC and a combination of both BM-MSC and AD-MSC.

Detailed description

The aim of the present study will be to compare 3 types of intra-articular injections of MSC populations obtained from two clinically relevant sources: injections containing BM-MSC or AD-MSC or a combination of both BM-MSC,and AD-MSC in a randomized non blind clinical trial. To assess the efficacy and safety of 3 kind of MSC injections in relation to pain, function and quality of life in patients with knee OA. A total of 54 patients with the diagnosis of knee OA grade II and III will be recruited to receive a single intra-articular injection of MSC: Group 1 (n 18 patients) will receive BM-MSC, Group 3 (n 18 patients) will receive AD-MSC. Group 3 (18 patients) will receive a combination of BM-MSC and AD-MSC. A randomized non blind clinical trial with active control. For this purpose, the random number generator is 54, found on the RANDOM.ORG ® website (available at https://www.random.org/integers/)

Interventions

intrarticular bone marrow mesenchymal stem cells injection

intrarticular adipose mesenchymal stem cells injection

BIOLOGICALbone marrow & adipose mesenchymal stem cells injection

intrarticular bone marrow and adipose stem cells injection.

Sponsors

Maastricht University Medical Center
CollaboratorOTHER
Universidad Catolica Santiago de Guayaquil
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Masking description

A randomized non blind clinical trial with active control. For this purpose, the random number generator, found on the RANDOM.ORG ® website (available at https://www.random.org/integers/)

Intervention model description

A total of 54 patients with the diagnosis of knee OA grade II and III will be recruited to receive a single intra-articular injection of MSC: Group 1 (n 18 patients) will receive BM-MSC, Group 2 (n 18 patients) will receive AD-MSC. Group 3 (18 patients) will receive a combination of BM-MSC and AD-MSC.

Eligibility

Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

* Patients aged 18 to 70 years, with grade II and III knee OA, according to the Ahlbäck classification will be included. * Minimal VAS pain score of 4. * Chronic knee pain of mechanical origin. * All patients who sign a specially prepared informed consent for this clinical trial.

Exclusion criteria

* Varus or valgus knee mal alignment superior to 10°. * OA grade IV according Ahlbäck classification. * Bone marrow cancer like lymphoma. * Severe anemia. * Active infections. * Pregnant patients. * Inmune diseases such as Rheumatoid arthritis, gout or pseudogout arthritis, psoriasis. * Bone diseases such as Kahler and Paget. * Corticoesteroid and hyaluronic injections within the last 3 months. * Knee surgery in the last 6 months.

Design outcomes

Primary

MeasureTime frameDescription
knee pain assessed by Visual Analogue Scale.12 monthspsychometric response scale which used in questionnaires. It is a measurement instrument for subjective characteristics of pain . Score from O to 10. O indicate no pain, and 10 indicate the worst pain.
knee function assessed by WOMAC (Wester Ontario McMaster Osteoarthritis Index). quosteionary.12 monthsThe Index contains 24 questions five items for pain (score range 0-20), two for stiffness (score range 0-8), and 17 for functional limitation (score range 0-68). Individual question responses are assigned a score of between 0 (extreme) and 4 (None). Individual question scores are then summed to form a raw score ranging from 0 (worst) to 96 (best). Finally, raw scores are normalized by multiplying each score by 100/96. This produces a reported WOMAC Score of between 0 (worst) to 100 (best).

Secondary

MeasureTime frameDescription
Quantitative T2-Mapping Evaluation of Changes in Cartilage Matrix6 months after procedureMRI T2 mapping of the cartilage is a non-invasive functional imaging technique delivering cartography of the T2 relaxation time of the cartilage without any contrast injection. It is sensitive to tissue anisotropy, and provides compositional information on the cartilage collagen network, water content and proteoglycans concentration.

Countries

Ecuador

Contacts

Primary ContactCarlos A Chiriboga, MD
drcarloschiriboga@gmail.com593 9 9995 4148
Backup ContactPeter A Chedraui, Phd
peter.chedraui@cu.ucsg.edu.ec593 9 9942 4629

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026